In a bid to tap the $452-million Fexofenadine drug market, Dr Reddy’s Laboratories today announced the launch of generic version of Allegra — Fexofenadine HCl — tablets in the US market.
The Food & Drug Administration (FDA) approved Dr Reddy’s abbreviated new drug application (ANDA) for Fexofenadine HCl tablets on April 12.
The pharmaceutical firm will market the over-the-counter product under store brand labels in the US market.
The products are bio equivalent versions of Sanofi-Aventis’ Allegra tablets which received Rx-to-OTC switch approval from the FDA on January 24.
In January, the US District Court of New Jersey cleared the decks for Dr Reddy’s Laboratories, the country’s second-biggest drug maker, to launch the generic version of Allegra-D 24 in the US.
The US Court had also ordered Sanofi-Aventis and Albany Molecular Research, which had earlier obtained an injunction against launching of the drug, to post a security of $40 million with the court towards the possibility that the injunction had been wrongfully granted.
Earlier, based on a request filed by AMRI and Sanofi-Aventis, the US District Court had granted a preliminary injunction on the launch of Allegra-D 24 (fexofenadine hydrochloride / pseudoephedrine hydrochloride 180/240 mg extended release tablet) in June last year.
In September 2009, AMRI filed a patent infringement lawsuit in the court against Dr Reddy’s for infringement of one of AMRI’s patents, related to the manufacturing process for the active ingredient in Allegra, Allegra-D 12, and Allegra-D 24 Hour.
AMRI joined hands with French drug maker Sanofi-Aventis SA, which sells Allegra and filed the law suit.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.